These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 18591159

  • 1. Quantum dots-based multiplexed immunohistochemistry of protein expression in human prostate cancer cells.
    Shi C, Zhou G, Zhu Y, Su Y, Cheng T, Zhau HE, Chung LW.
    Eur J Histochem; 2008; 52(2):127-34. PubMed ID: 18591159
    [Abstract] [Full Text] [Related]

  • 2. Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells.
    Arnold JT, Liu X, Allen JD, Le H, McFann KK, Blackman MR.
    Prostate; 2007 Aug 01; 67(11):1152-62. PubMed ID: 17503469
    [Abstract] [Full Text] [Related]

  • 3. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
    Ishikura N, Kawata H, Nishimoto A, Nakamura R, Ishii N, Aoki Y.
    Prostate; 2010 Apr 01; 70(5):457-66. PubMed ID: 19902465
    [Abstract] [Full Text] [Related]

  • 4. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.
    Kokontis JM, Hsu S, Chuu CP, Dang M, Fukuchi J, Hiipakka RA, Liao S.
    Prostate; 2005 Dec 01; 65(4):287-98. PubMed ID: 16015608
    [Abstract] [Full Text] [Related]

  • 5. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.
    Cherian MT, Wilson EM, Shapiro DJ.
    J Biol Chem; 2012 Jul 06; 287(28):23368-80. PubMed ID: 22589544
    [Abstract] [Full Text] [Related]

  • 6. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.
    Br J Cancer; 1999 Sep 06; 81(2):242-51. PubMed ID: 10496349
    [Abstract] [Full Text] [Related]

  • 7. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L, Giocanti N, Hennequin C, Favaudon V.
    Prostate; 2010 Mar 01; 70(4):401-11. PubMed ID: 19902473
    [Abstract] [Full Text] [Related]

  • 8. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
    Ishikura N, Kawata H, Nishimoto A, Nakamura R, Tsunenari T, Watanabe M, Tachibana K, Shiraishi T, Yoshino H, Honma A, Emura T, Ohta M, Nakagawa T, Houjo T, Corey E, Vessella RL, Aoki Y, Sato H.
    Int J Oncol; 2015 Apr 01; 46(4):1560-72. PubMed ID: 25634071
    [Abstract] [Full Text] [Related]

  • 9. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
    Sadar MD, Gleave ME.
    Cancer Res; 2000 Oct 15; 60(20):5825-31. PubMed ID: 11059779
    [Abstract] [Full Text] [Related]

  • 10. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
    Pandini G, Mineo R, Frasca F, Roberts CT, Marcelli M, Vigneri R, Belfiore A.
    Cancer Res; 2005 Mar 01; 65(5):1849-57. PubMed ID: 15753383
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells.
    Lu S, Wang A, Lu S, Dong Z.
    Mol Cancer Ther; 2007 Jul 01; 6(7):2057-64. PubMed ID: 17620434
    [Abstract] [Full Text] [Related]

  • 13. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
    Wang Y, Liu G, Tong D, Parmar H, Hasenmayer D, Yuan W, Zhang D, Jiang J.
    Prostate; 2015 Aug 01; 75(11):1187-96. PubMed ID: 25894097
    [Abstract] [Full Text] [Related]

  • 14. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
    Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H.
    Cancer Res; 1994 Oct 15; 54(20):5474-8. PubMed ID: 7522959
    [Abstract] [Full Text] [Related]

  • 15. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C, Wafa LA, Lamoureux F, Cheng H, Fazli L, Gleave ME, Rennie PS.
    Prostate; 2012 Jun 01; 72(8):875-85. PubMed ID: 22072572
    [Abstract] [Full Text] [Related]

  • 16. Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A.
    Desiniotis A, Schäfer G, Klocker H, Eder IE.
    Int J Cancer; 2010 Feb 01; 126(3):775-89. PubMed ID: 19653278
    [Abstract] [Full Text] [Related]

  • 17. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
    Hodgson MC, Astapova I, Hollenberg AN, Balk SP.
    Cancer Res; 2007 Sep 01; 67(17):8388-95. PubMed ID: 17804755
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP.
    Swinnen JV, Esquenet M, Goossens K, Heyns W, Verhoeven G.
    Cancer Res; 1997 Mar 15; 57(6):1086-90. PubMed ID: 9067276
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.